Media Room Menu
UPDATED STUDY RESULTS REINFORCE SURVIVAL BENEFIT OF TAXOTERE® (DOCETAXEL) FOR MEN WITH ADVANCED, HORMONE-RESISTANT PROSTATE CANCER
